The University of Navarra and the company 3P Biopharmaceuticals will promote research and talent management in technology and the production of new drugs.

This collaboration agreement aims to reinforce the figure of the pharmacist and other health science professionals as expert scientists, to collaborate with the academic world in developing industrial knowledge and drug manufacturing, and to promote their training.

Agreement signed to promote digital transformation and the training of professionals focused on the pharmaceutical industry.

La Universidad y la empresa 3P Biopharmaceuticals potenciarán la investigación y la gestión de talento en tecnología y producción de nuevos medicamentos

The University of Navarra and the company 3P Biopharmaceuticals have signed an agreement to promote training and research in technology and the production of new drugs, especially biotechnological ones. This collaboration agreement aims to reinforce the figure of the pharmacist and other health science professionals as expert scientists, to collaborate with the academic world in developing industrial knowledge and drug manufacturing, and to promote their training.

The agreement also aims to maximize the use of new technologies and promote the digital transformation of the pharmaceutical industry. The collaboration between the University of Navarra and 3P Biopharmaceuticals, a leader in the development of processes and manufacturing of biopharmaceutical and cell therapy products, has a clear aim of helping society and will have an interdisciplinary group of experts with complementary specializations and knowledge.

The areas of interest of this agreement address new medicine and advanced therapies in R&D, among others, the development of biological drugs and cell and gene therapy, manufacturing and analytical technology, and dispensing technology, with the goal of manufacturing increasingly safer drugs, with increasingly fewer side effects, or oriented to diseases that, until now, have no cure or with treatments with serious side effects.

Strengthening Navarre’s strategic commitment to health

For the Vice-Rector for Research at the University of Navarra, Iciar Astiasarán, “COVID-19 and the development of several types of vaccines in record time have demonstrated the importance of a solid healthcare system and research and innovation in the world of medicine. We are confident that our agreement with 3P Biopharmaceuticals will enhance Navarra’s strategic commitment to health for all citizens.”

According to the CEO of 3P Biopharmaceuticals, Dámaso Molero, “through this agreement 3P shows its support for creating technical-scientific talent that contributes knowledge to a growing and dynamic sector such as biotechnology. I hope that as a result of this collaboration, we will continue to add value to Navarra and the Spanish biopharmaceutical sector”.

The University of Navarra and 3P Biopharmaceuticals also want to promote biopharmaceutical bachelor’s and master’s degree studies, for which prizes and scholarships will be created. The pharmaceutical company and the academic center will organize activities, courses, seminars, and scientific meetings. The agreement has been signed for a period of five years. The company 3P Biopharmaceuticals undertakes to finance the necessary equipment and materials and to make its facilities available to the academic centre. The University, for its part, will be responsible for disseminating and publishing the results and advances resulting from this collaboration agreement.

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.